PubRank

Daniel J George

Author PubWeight™ 110.93‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2012 15.69
2 Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006 11.33
3 Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2005 9.05
4 Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012 5.25
5 Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Natl Acad Sci U S A 2003 3.34
6 Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res 2011 3.25
7 Sunitinib efficacy against advanced renal cell carcinoma. J Urol 2007 3.14
8 Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008 3.00
9 Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. J Clin Oncol 2012 2.56
10 Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. J Clin Oncol 2012 2.48
11 Public survey and survival data do not support recommendations to discontinue prostate-specific antigen screening in men at age 75. Urology 2009 2.09
12 Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 2008 1.94
13 Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras. J Urol 2009 1.85
14 Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005 1.68
15 ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol 2012 1.66
16 Novel immunotherapeutic strategies in development for renal cell carcinoma. Eur Urol 2012 1.60
17 Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416. Ophthalmology 2002 1.45
18 The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer 2009 1.45
19 Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res 2004 1.42
20 Development of an integrated prostate cancer research information system. Clin Genitourin Cancer 2006 1.36
21 A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 2008 1.22
22 Plasma levels of heat shock protein 70 in patients with prostate cancer: a potential biomarker for prostate cancer. Clin Prostate Cancer 2004 1.14
23 Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother 2007 1.10
24 A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. Clin Cancer Res 2010 1.09
25 Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference. Clin Cancer Res 2007 1.07
26 Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. Urology 2005 1.03
27 Innovations and challenges in renal cancer: consensus statement from the first international conference. Clin Cancer Res 2004 1.02
28 Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Manag Res 2013 1.00
29 Mutations in ribonuclease L gene do not occur at a greater frequency in patients with familial prostate cancer compared with patients with sporadic prostate cancer. Clin Prostate Cancer 2003 0.96
30 Bone marrow biopsy: RNA isolation with expression profiling in men with metastatic castration-resistant prostate cancer--factors affecting diagnostic success. Radiology 2013 0.95
31 A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer. Urol Oncol 2011 0.95
32 Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate Center. J Urol 2011 0.94
33 Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer. J Urol 2011 0.93
34 A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer. Clin Genitourin Cancer 2013 0.93
35 Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors. Clin Genitourin Cancer 2012 0.89
36 Cell signaling modifiers in prostate cancer. Cancer J 2008 0.88
37 Clinical endpoints for drug development in prostate cancer. Curr Opin Urol 2008 0.86
38 Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology 2002 0.86
39 A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer. Clin Cancer Res 2005 0.86
40 Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma. Clin Genitourin Cancer 2007 0.84
41 New drug development in metastatic prostate cancer. Urol Oncol 2008 0.83
42 Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review. Curr Med Res Opin 2013 0.83
43 "Real world" treatment of metastatic renal cell carcinoma in a joint community-academic cohort: progression-free survival over three lines of therapy. Clin Genitourin Cancer 2013 0.82
44 Use of "Real-World" data to describe adverse events during the treatment of metastatic renal cell carcinoma in routine clinical practice. Med Oncol 2014 0.82
45 Satraplatin in the treatment of hormone-refractory metastatic prostate cancer. Ther Clin Risk Manag 2007 0.81
46 Does the multidisciplinary approach improve oncological outcomes in men undergoing surgical treatment for prostate cancer? Int J Urol 2014 0.81
47 Update in the management of patients with hormone-refractory prostate cancer. Curr Opin Urol 2005 0.80
48 Bevacizumab and everolimus in renal cancer: a rational way forward. J Clin Oncol 2010 0.80
49 Anti-angiogenic therapy in renal cell cancer. BJU Int 2007 0.80
50 Current standard and investigational approaches to the management of hormone-refractory prostate cancer. Rev Urol 2007 0.79
51 Tyrosine kinase inhibitors in renal cell carcinoma. Clin Cancer Res 2004 0.78
52 Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure. J Oncol Pract 2013 0.78
53 Decreases in free cholesterol and fatty acid unsaturation in renal cell carcinoma demonstrated by breath-hold magnetic resonance spectroscopy. Am J Physiol Renal Physiol 2004 0.78
54 Real-world outcomes in metastatic renal cell carcinoma: insights from a Joint Community-Academic Registry. J Oncol Pract 2013 0.77
55 Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer. Expert Opin Pharmacother 2014 0.77
56 Is tumor response important for renal carcinoma? Eur Urol 2010 0.77
57 Bevacizumab as a treatment option in advanced renal cell carcinoma: an analysis and interpretation of clinical trial data. Cancer Treat Rev 2010 0.77
58 Response to docetaxel/carboplatin in patients with hormone-refractory prostate cancer not responding to taxane-based chemotherapy. Clin Prostate Cancer 2005 0.77
59 Prediagnostic plasma vascular endothelial growth factor levels and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2005 0.77
60 Better late than early: FDG-PET imaging in metastatic renal cell carcinoma. Clin Cancer Res 2011 0.76
61 Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer. Cancer Chemother Pharmacol 2014 0.76
62 Targeted therapy in renal cell carcinoma. Expert Opin Investig Drugs 2005 0.76
63 Rapid rise of serum prostate specific antigen levels after discontinuation of the herbal therapy PC-SPES in patients with advanced prostate carcinoma: report of four cases. Cancer 2002 0.76
64 Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T? Clin Med Insights Oncol 2011 0.75
65 Reply to M A Khattak et al. J Clin Oncol 2013 0.75
66 How Can We Effectively Address the Medical and Psychological Concerns of Survivors of Pelvic Malignancies? Oncology (Williston Park) 2017 0.75
67 Novel chemotherapies in development for management of castration-resistant prostate cancer. Curr Opin Urol 2013 0.75
68 A phase II trial of interferon-alpha and toremifene in advanced renal cell cancer patients. Cancer Invest 2002 0.75
69 Incidental discovery of an appendiceal carcinoid tumor and a renal cell carcinoma. Clin Adv Hematol Oncol 2003 0.75
70 Immunotherapy in cancer care: understanding the impact of shifting treatment paradigms in the managed care setting. Am J Manag Care 2014 0.75
71 What to order from the prostate cancer treatment menu? Oncology (Williston Park) 2012 0.75
72 Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United States. Curr Med Res Opin 2014 0.75
73 Immunotherapy in cancer care: understanding the impact of shifting treatment paradigms in the managed care setting. Am J Manag Care 2014 0.75
74 Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United States. Expert Opin Pharmacother 2015 0.75